Menu
Search
|

Menu

Close
X

Pacira Pharmaceuticals Inc PCRX.OQ (NASDAQ Stock Exchange Global Select Market)

30.55 USD
+0.40 (+1.33%)
As of Feb 22
chart
Previous Close 30.15
Open 30.30
Volume 200,027
3m Avg Volume 223,393
Today’s High 30.85
Today’s Low 29.65
52 Week High 58.80
52 Week Low 29.38
Shares Outstanding (mil) 40.34
Market Capitalization (mil) 1,474.48
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.47 Mean rating from 19 analysts

KEY STATS

Revenue (mm, USD)
FY17
140
FY16
276
FY15
249
EPS (USD)
FY17
-1.014
FY16
-1.018
FY15
0.042
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
5.24
5.77
Price to Book (MRQ)
vs sector
5.65
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
103.29
16.52
LT Debt to Equity (MRQ)
vs sector
103.17
12.22
Return on Investment (TTM)
vs sector
-16.47
14.43
Return on Equity (TTM)
vs sector
-26.87
16.13

EXECUTIVE LEADERSHIP

David Stack
Chairman of the Board, Chief Executive Officer, Since 2015
Salary: $761,346.00
Bonus: $396,344.00
Charles Reinhart
Chief Financial Officer, Since 2016
Salary: $269,231.00
Bonus: $85,500.00
Scott Braunstein
Chief Operating Officer, Since 2017
Salary: $419,039.00
Bonus: $134,400.00
James Jones
Senior Vice President, Chief Medical Officer, Since 2015
Salary: $154,327.00
Bonus: $120,000.00
Kristen Williams
Chief Administrative Officer, General Counsel, Secretary, Since 2014
Salary: $417,308.00
Bonus: $134,400.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

5 Sylvan Way Ste 300
PARSIPPANY   NJ   07054-3813

Phone: +1973.2543560

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.

SPONSORED STORIES